Evolus (EOLS) AI Stock Analysis

• Market Cap: $586.73M
• Dividend Yield: N/A
• Average Volume (3M): 1.06M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.13
• Revenue Growth: 25.38%
• EPS Growth: 15.00%
• Country: US
• Employees: 372
• Sector: Healthcare
• Sector Strength: 46
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.15
• Shares Outstanding: 64,475,586
• 10 Day Avg. Volume: 993,458
• 30 Day Avg. Volume: 1,057,563
• PEG Ratio: -0.14
• Price to Book (P/B): 22.76
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -35.95
• Enterprise Value/Market Cap: 0.75
• Enterprise Value/Revenue: 0.43
• Enterprise Value/Gross Profit: 2.36
• Enterprise Value/Ebitda: -2.72
• 1Y Price Target: $24.00
• Price Target Upside: 162.58% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 44 Neutral
• Price Target: $9.00 ▼(-1.53%Downside)

Evolus faces significant financial challenges, with negative profitability and valuation concerns being the most impactful factors. However, strategic execution, strong revenue growth, and improved financial flexibility through recent corporate events provide some positive outlook.

Positive Factors

Financial Performance

Evolus reported global net revenue of $68.5M in 1Q25, a 15.5% increase from 1Q24, driven primarily by higher volumes and market share gains.

Market Performance

Jeuveau significantly outperformed the overall toxin market and the leading toxin Botox to further grow its market share.

Product Launch

There is a positive outlook for the exciting new launch of a second product line with Evolysse.

Negative Factors

Executive Changes

CFO Sandra Beaver will be resigning from the company and Evolus has initiated the process to identify a successor.

Macroeconomic Concerns

Some investors may be concerned with the macro trends, given the significant volatility in the capital markets, consumer sentiment, and tariffs noise.

Evolus Business Overview & Revenue Model

Company Description

Evolus, Inc. (EOLS) is a performance beauty company that focuses on delivering innovative aesthetic products. The company's flagship product, Jeuveau, is a prescription medicine used in facial aesthetics to improve the appearance of moderate to severe frown lines between the eyebrows, also known as glabellar lines. Evolus specializes in the self-pay aesthetic market, emphasizing the millennial consumer segment through its contemporary branding and digital marketing strategies.

How the Company Makes Money

Evolus generates revenue primarily through the sale of its aesthetic product, Jeuveau, to healthcare providers and practitioners who administer the treatment to patients. The company leverages a competitive pricing strategy to capture market share in the aesthetic neurotoxin market, traditionally dominated by larger players. Additionally, Evolus's revenue model benefits from its direct sales force, which works closely with aesthetic professionals to drive product adoption and usage. Strategic partnerships with partners such as Daewoong Pharmaceutical Co., Ltd., which manufactures Jeuveau, contribute to the company's supply chain efficiency and product availability. Evolus also engages in promotional activities and loyalty programs aimed at both healthcare providers and end consumers to enhance product visibility and drive sales.

Evolus Financial Statement Overview

Summary

Evolus faces significant financial challenges despite revenue growth. The company operates at a net loss with negative EBIT and EBITDA margins. Its balance sheet shows negative stockholders' equity, and cash flow from operations remains negative, indicating reliance on external financing.

Income Statement

Evolus has shown steady revenue growth with a notable increase in total revenue from $56.54M in 2020 to $275.02M in the TTM period ending March 2025. Despite this, the company continues to operate at a net loss, with consistently negative EBIT and EBITDA margins. The net profit margin remains negative, indicating ongoing profitability challenges.

Balance Sheet

The balance sheet reflects significant financial instability, with negative stockholders' equity in recent periods, indicating potential solvency issues. The debt-to-equity ratio is not meaningful due to negative equity, but the overall liabilities exceed assets, pointing to financial leverage concerns. This highlights a need for improved capitalization and risk management.

Cash Flow

Cash flow from operations is consistently negative, although the company has managed to reduce its cash outflows over time. The free cash flow remains negative, suggesting ongoing challenges in generating cash from operations. The company's reliance on financing activities to manage liquidity is evident.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	275.01M	266.27M	202.09M	148.62M	99.67M	56.54M
Gross Profit	186.27M	182.30M	140.53M	92.73M	56.14M	38.24M
EBITDA	-53.43M	-25.00M	-41.81M	-60.72M	-39.06M	-144.75M
Net Income	-56.20M	-50.42M	-61.69M	-74.41M	-46.81M	-163.01M
Balance Sheet
Total Assets	213.36M	232.57M	189.00M	177.98M	257.48M	209.07M
Cash, Cash Equivalents and Short-Term Investments	67.89M	86.95M	62.84M	53.92M	146.26M	107.56M
Total Debt	8.39M	129.98M	126.55M	73.20M	74.74M	138.32M
Total Liabilities	219.97M	227.05M	209.69M	159.48M	175.61M	282.03M
Stockholders Equity	-6.60M	5.52M	-20.69M	18.50M	-422.88M	-376.07M
Cash Flow
Free Cash Flow	-24.93M	-19.47M	-35.63M	-11.71M	-34.36M	-61.01M
Operating Cash Flow	-23.02M	-18.00M	-34.01M	-8.77M	-33.39M	-57.87M
Investing Cash Flow	-5.89M	-4.82M	-1.63M	-1.39M	4.03M	12.19M
Financing Cash Flow	121.00K	47.41M	44.64M	-1.52M	73.05M	38.35M

Evolus Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 9.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EOLS, the sentiment is Negative. The current price of 9.14 is below the 20-day moving average (MA) of 9.65, below the 50-day MA of 10.19, and below the 200-day MA of 12.76, indicating a bearish trend. The MACD of -0.25 indicates Positive momentum. The RSI at 40.74 is Neutral, neither overbought nor oversold. The STOCH value of 13.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EOLS.

Evolus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SIGA	80 Outperform	$461.51M	9.51	25.47%	10.13%	-23.37%	-39.03%
COLL	71 Outperform	$957.52M	24.64	19.23%	―	17.17%	-51.97%
AVDL	63 Neutral	$891.42M	―	-34.65%	―	252.64%	85.10%
ORGO	49 Neutral	$449.06M	928.57	-4.92%	―	5.35%	-432.51%
TLRY	48 Neutral	$415.98M	―	-31.06%	―	11.22%	-108.58%
Sector *	46 Neutral	C$190.36M	-4.25	-8.56%	3.10%	13.57%	-1.98%
EOLS	44 Neutral	$586.73M	―	-949.46%	―	25.38%	15.00%

Evolus Corporate Events

Evolus Announces Board Changes and Director Elections

On June 5, 2025, Evolus, Inc. experienced significant changes in its board of directors as part of a planned transition, with Simone Blank stepping down and Albert White III joining the Audit Committee. Additionally, during the Annual Meeting of Stockholders, David Gill and Albert White III were elected as Class I Directors, Ernst & Young LLP was ratified as the independent accounting firm, and the compensation of the company’s executive officers was approved.

The most recent analyst rating on (EOLS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Evolus stock, see the EOLS Stock Forecast page.

Evolus CFO Sandra Beaver Announces Resignation

On May 27, 2025, Evolus, Inc. announced the voluntary resignation of its Chief Financial Officer, Sandra Beaver, effective June 13, 2025, as she moves to a new opportunity in a private mental health and wellness technology company. The company emphasized that her departure was not due to any disagreements related to its operations or financial practices. CEO David Moatazedi acknowledged Beaver’s contributions to Evolus’ growth and success, noting the company’s strong momentum with recent product launches and record revenues. Evolus has initiated a search for her successor while its experienced finance team ensures a smooth transition.

The most recent analyst rating on (EOLS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Evolus stock, see the EOLS Stock Forecast page.

Evolus Secures New $250 Million Credit Facility

On May 5, 2025, Evolus, Inc. announced an amended and restated credit facility, replacing its existing $125 million credit agreement with a new $250 million facility managed by Pharmakon Advisors, LP. This refinancing reduces the company’s interest expenses, enhances financial flexibility, and provides additional capital availability. The new agreement includes a lower interest rate and a conversion to a bullet maturity payment structure, eliminating pre-payment fees from the existing facility. This strategic move is expected to improve Evolus’ cash generation and support its commercial momentum and strategic initiatives.